【Major Developments】Insilico (03696) has been added as a constituent of the Hang Seng Composite Index. Seyond (02665) has been added as a constituent of the Hang Seng Composite Index. CF Pharmtech (02652) has been added as a constituent of the Hang Seng Composite Index. Hansoh Pharma (03692): Aumolertinib Mesylate Tablets for monotherapy have been approved for marketing in the European Union. Clearbridge Biomedics-B (02592): The new drug clinical trial application for CBT-199 has taken effect, and the clinical trial has been deemed safe to proceed. Sino Biopharm (01093): A long-acting injection of a GLP-1/GIP receptor dual-biased agonist polypeptide has received clinical trial approval in the United States. Sino Biopharm (01093): A long-acting Ropivacaine injection (SYH9089 injection) has received clinical trial approval in China. Henlius Biotech (02696): The Phase 1 clinical trial application for HLX15-SC (recombinant fully human anti-CD38 monoclonal antibody injection for subcutaneous use) for the treatment of multiple myeloma has been approved by the US FDA.

【Financial Data】China Shougang Resources (00639) issued a profit warning, forecasting consolidated profit attributable to company owners for the 2025 fiscal year to be approximately HK$600 million to HK$700 million. Sihuan Pharmaceutical (02005) issued a profit warning, expecting annual profit attributable to equity holders to decrease by approximately 45% to 60% year-on-year. Goodbaby International (01086) issued a profit warning, anticipating a net profit decrease of approximately 35% to 45% for 2025. Robosense (02498) reported continued growth in LiDAR product sales for the 2025 fiscal year, achieving profitability for the first time in a single quarter during Q4.